We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Breast Biopsy Technology Integrated into Ultrasound System

By HospiMedica staff writers
Posted on 08 Nov 2007
Two medical companies are combining their resources to provide new breast biopsy ultrasound technology.

SenoRx, Inc. More...
(Akiso Viejo, CA, USA) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SenoSonix system, an integration of its EnCor breast biopsy system with a state-of-the-art ultrasound imaging system. The device incorporates SenoRx's proprietary EnCor vacuum-assisted biopsy technologies with an ultrasound system developed and sold by Ultrasonix Medical Corp. (Richmond, Canada).

SenoRx and Ultrasonix are jointly developing the technology, facilitating the integration of the two products. The product will be branded SenoSonix and marketed as SenoSonix with EnCor Inside. Ultrasonix launched its innovative Sonix series of Smart ultrasound systems in 2005 and has placed over 1,000 systems worldwide. Launching its flagship EnCor system in November 2005, SenoRx currently has an installed base of more than 400 of its breast biopsy systems in the United States and Canada.

"We will position the SenoSonix device to compete in the physician's office segment for those surgeons performing vacuum-assisted biopsies in their office,” said Lloyd Malchow, SenoRx president and chief executive officer. "We believe that the market segment is currently small, but growing rapidly. We further believe that the value and convenience proposition for this product may be compelling in markets outside the United States, which currently perform a significant percentage of biopsy procedures using ultrasound.”

"We believe that the SenoSonix system will uniquely address the breast biopsy market with a cost-effective solution that provides high-quality ultrasound imaging and guidance with vacuum-assisted breast biopsy capability in one device. The compact size and intuitive user interface of the SenoSonix system makes it attractive for the physician's office,” said John Buhler, Ultrasonix chief executive officer.

SenoRx develops, manufactures, and sells minimally invasive medical devices used by breast care specialists for the diagnosis of breast cancer. Ultrasonix Medical focuses on development and manufacturing of diagnostic ultrasound imaging systems.


Related Links:
SenoRx
Ultrasonix Medical

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.